BTBP(SH:600161)2018-01-19 16:00Financial Performance - The company's net profit attributable to shareholders is expected to increase by 913.87 million yuan, a year-on-year increase of approximately 349%[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to increase by 164.55 million yuan, a year-on-year increase of approximately 67%[3] - The net profit from the blood products business is expected to be 451.56 million yuan, a year-on-year increase of approximately 11%[5] Non-Recurring Gains - Non-recurring gains and losses attributable to shareholders are expected to be 766.56 million yuan, primarily from the transfer of 100% equity in Beijing Beishengyan Biological Products Co., Ltd. and 51% equity in Changchun Qijian Biological Products Co., Ltd., totaling 758.44 million yuan[2] - The company achieved an investment income of 758.44 million yuan (after tax) from the transfer of equity stakes in two subsidiaries[5] Revenue Growth - The company's blood products business revenue is expected to reach 1.51539 billion yuan, a year-on-year growth of approximately 16%[5] Earnings Per Share - The earnings per share for the previous year was 0.51 yuan, which will be adjusted to 0.38 yuan after the stock split[4] Performance Forecast - The company has no significant uncertainties affecting the accuracy of this performance forecast[6] - The data provided is preliminary and subject to final audited financial statements[7]